Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Bone Scintigraphy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    94 result(s) found for: Bone Scintigraphy. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2010-024624-20 Sponsor Protocol Number: OCRD2010/22 Start Date*: 2011-07-12
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and University of Cambridge
    Full Title: A Pilot Study Investigating the Sensitivity of 18F-labelled Sodium Fluoride PET-CT for Detecting Skeletal Metastases in Renal Cell Carcinoma compared to Planar Bone Scintigraphy and Multidetector CT
    Medical condition: Metastatic renal cell carcinoma.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-000885-20 Sponsor Protocol Number: Ibondronate Start Date*: 2007-07-20
    Sponsor Name:academic hospital Maastricht
    Full Title: Open label study to establish the efficacy of intravenous loading doses of Ibandronate 6 mg in patients with lung cancer and skeletal metastased experiencing moderate to severe bone pain.
    Medical condition: Patients with lung cancer and malignant disease to bone.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-002089-13 Sponsor Protocol Number: NB 2006 xx Start Date*: 2006-05-26
    Sponsor Name:University Hospitals of Leicester NHS Trust
    Full Title: International Phase II Studies of 131I-mIBG in combination with topotecan and peripheral blood stem cell rescue for (A) primary resistant high risk neuroblastoma and (B) relapsed stage 4 neuroblast...
    Medical condition: Neuroblastoma
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-000299-15 Sponsor Protocol Number: BC1-03 Start Date*: 2004-11-03
    Sponsor Name:Algeta AS
    Full Title: A double-blind, dose-response, phase II, multicentre study of radium-223 (Alpharadin TM ) for the palliation of painful bone metastases in hormone refractory prostate cancer patients
    Medical condition: The target population is patients suffering from bone pain due to skeletal metastasis secondary to prostate cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-002415-10 Sponsor Protocol Number: PROCoMBO Start Date*: 2014-02-11
    Sponsor Name:University Medical Center Groningen
    Full Title: [18F]-labelled FDHT in PET/CT for detection and staging of bone metastases in hormone naïve prostate cancer
    Medical condition: Hormone naive prostate cancer, metastasized to bone (2 or more bone metastases).
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-012189-30 Sponsor Protocol Number: BC1-09 Start Date*: 2009-10-30
    Sponsor Name:Algeta ASA
    Full Title: An open-label Phase IIa, non-randomised, study of Alpharadin in breast cancer patients with bone dominant disease who are no longer considered suitable for endocrine therapy
    Medical condition: Breast cancer patients with bone dominant disease who have progressed on endocrine therapy and are no longer considered suitable for further endocrine therapy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027452 Metastases to bone LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-001815-19 Sponsor Protocol Number: Ga-68-PSMA-11 Start Date*: 2017-08-04
    Sponsor Name:Deutsches Krebsforschungszentrum (DKFZ), Stiftung des öffentlichen Rechts
    Full Title: An open-label, single-arm, rater-blinded, multicenter phase 1/2 study to assess safety and diagnostic accuracy and radiotherapeutic implications of pre-operative Ga-68-PSMA-11 PET/CT imaging in com...
    Medical condition: Prostate cancer (PCA) with high risk of metastasis.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2016-003121-42 Sponsor Protocol Number: CHDR1635 Start Date*: 2019-11-28
    Sponsor Name:Enceladus Pharmaceuticals BV
    Full Title: A Phase I-IIa, Open label, Dose Escalating Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Intravenous Pegylated Liposomal Dexamethasone Sodium Phosphate as Monotherapy in Pa...
    Medical condition: Castration resistant prostate cancer with bone metastases.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005327-41 Sponsor Protocol Number: INT0211 Start Date*: 2012-04-05
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: Clinical trial randomized and controlled to compare the analgesic efficacy of the association zoledronic acid and 153Sm-lexidronam vs zoledronic acid in patients with skeletal metastases from hormo...
    Medical condition: Population enrolled in the study is represented by patients bearing advanced prostatic cancer with skeletal metastases and bone pain cancer-associated and treated with analgesic drugs
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005993 Bone metastases LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-014839-21 Sponsor Protocol Number: 2008-CaP-FCH Start Date*: 2009-10-09
    Sponsor Name:CIS bio international, member of IBA group
    Full Title: Diagnostic value of 18F-choline PET/CT for the detection of systemic prostate cancer disease.
    Medical condition: de novo patients with histologically confirmed prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    12.0 10060862 Prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-003760-47 Sponsor Protocol Number: 2018-14 Start Date*: 2020-04-06
    Sponsor Name:Assistance Publique Hôpitaux de Marseille
    Full Title: Evaluation of 68Ga-PSMA PET-CT in the initial extension assessment of advanced renal cell carcinoma a prospective, multicenter, open study
    Medical condition: renal cell cancer (RCC)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-006195-11 Sponsor Protocol Number: BC1-06 Start Date*: 2008-03-26
    Sponsor Name:Algeta ASA
    Full Title: A double-blind, randomised, multiple dose, Phase III, multicentre study of Alpharadin in the treatment of patients with symptomatic hormone refractory prostate cancer with skeletal metastases.
    Medical condition: Hormone refractory prostate cancer with skeletal metastases
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027452 Metastases to bone PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed) FR (Completed) GB (Completed) BE (Completed) SK (Completed) ES (Completed) CZ (Completed) NL (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-002174-30 Sponsor Protocol Number: B3D-US-GHCV Start Date*: 2005-09-09
    Sponsor Name:Eli Lilly and Company
    Full Title: The Use of Nuclear Scintigraphy to Evaluate the Anabolic Effects of Teriparatide on the Skeleton in Postmenopausal Women in Osteoporosis
    Medical condition: Oesteoporosis
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-005373-58 Sponsor Protocol Number: 82/2007/O/Sper Start Date*: 2007-09-18
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: EVALUATION OF DIAGNOSTIC ACCURACY OF 68GA-CITRATE PET/CT IN PATIENTS WITH INFLAMMATORY-INFECTIOUS DISEASES.
    Medical condition: Inflammatory disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10005941 Bone and joint infections (excl arthritis) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-005435-98 Sponsor Protocol Number: version_2.0_dated_19.04.2011 Start Date*: 2012-06-21
    Sponsor Name:Śląski Uniwersytet Medyczny w Katowicach
    Full Title: A randomized, prospective, double-blind study with placebo to evaluate the efficacy of treatment of patients with angina resistant to pharmacological treatment and induced myocardial ischemia with...
    Medical condition: Stable angina pectoris CCS II-IV
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10049194 Stable angina pectoris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2014-002113-39 Sponsor Protocol Number: BAY88-8223/16298 Start Date*: 2014-10-29
    Sponsor Name:Bayer AG
    Full Title: A phase II randomized, double-blind, placebo-controlled trial of radium-223 dichloride versus placebo when administered to metastatic HER2 negative hormone receptor positive breast cancer subjects ...
    Medical condition: HER2 negative hormone receptor positive metastatic breast cancer with bone metastases treated with standard of care hormonal treatment.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) ES (Completed) AT (Completed) NO (Completed) CZ (Completed) DK (Prematurely Ended) NL (Completed) SE (Completed) PL (Completed) FI (Completed) IE (Completed) FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-004452-29 Sponsor Protocol Number: IRST185.04 Start Date*: 2017-04-12
    Sponsor Name:ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS
    Full Title: Randomized, multicentre phase II trial of the sequencing of Radium-223 and Docetaxel plus prednisone in symptomatic bone-only metastatic castration-resistant prostate cancer (mCRPC)
    Medical condition: symptomatic bone-only metastatic castration-resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10001186 Adenocarcinoma of prostate LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-004828-23 Sponsor Protocol Number: CR0701-21 Start Date*: 2010-04-01
    Sponsor Name:Cancer Research UK
    Full Title: A Cancer Research UK Phase II Trial to compare [11C]choline and [18F]choline each given as a single administration via intravenous injection for imaging patients with metastatic prostate cancer
    Medical condition: metastatic prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10036909 Prostate cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-001395-38 Sponsor Protocol Number: CALIPSO-study Start Date*: 2017-08-03
    Sponsor Name:AZIENDA USL DELLA VALLE D'AOSTA
    Full Title: Treatment of Metastatic prostate cancer castration resistant (mCRPC) with 223RaCl2: response evaluation with a novel tracer 68Ga-PSMA PET molecular imaging
    Medical condition: Patients mCRPC eligible to treatment with 223RaCl2
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005993 Bone metastases LLT
    20.1 100000004848 10036223 Positron emission tomography LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-003788-13 Sponsor Protocol Number: 1013 Start Date*: 2023-09-21
    Sponsor Name:Heikki Minn
    Full Title: Molecular theranostics for metastatic prostate cancer: PSMA, FAPI, or both?
    Medical condition: Metastatic prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FI (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 03:35:34 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA